Mapmygenome acquires Canada’s Microbiome Insights ahead of IPO

Hyderabad-based genomics company Mapmygenome strengthened its North American footprint with the acquisition of leading microbial sequencing firm Microbiome Insights.

May 29, 2025 - 23:00

Mapmygenome acquires Canada’s Microbiome Insights ahead of IPO

Mapmygenome, a genomics and microbiome testing company based in Hyderabad, has acquired Microbiome Insights, a Canadian contract research organisation specialising in microbial sequencing. The acquisition includes Microbiome Insights’ CAP-accredited laboratory and associated intellectual property.

The financial terms of the deal were not disclosed.

"The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors," declared Anu Acharya, Founder and CEO of Mapmygenome. "This accelerates our North American footprint aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year"

Founded by Dr Brett Finlay, Dr William Mohn, and Malcolm Kendall, Microbiome Insights has conducted over 1,000 microbiome studies for more than 600 academic, clinical, and industry clients globally, it said in a release. The organisation will continue to operate as a contract research partner for global microbiome research, while Mapmygenome introduces its genomics and microbiome services to North America.

Malcolm Kendall, CEO of Microbiome Insights, said the acquisition would help the company scale its operations. “Combining Mapmygenome’s AI-based genomics solutions with our expertise in microbiome science enhances our ability to support clients and pursue new opportunities,” he added.

Also Read

Navigating growth hurdles: Challenges faced by healthcare startups

Mapmygenome stated that the move is part of its international expansion strategy, with North America identified as a priority region in the lead-up to its planned IPO.

Founded in 2011, Mapmygenome offers personalised health solutions through DNA and microbiome testing. The company integrates genetic data with lifestyle, family history, and clinical insights to deliver customised health reports aimed at disease prevention, wellness, and improved health outcomes.

Its flagship offering, Genomepatri, provides insights into an individual’s genetic predisposition to various health conditions, along with information on nutrition, fitness, drug response, and wellness traits. In addition to personal genomics, the company also offers clinical genetic tests for inherited disorders, cancer risk assessments, carrier screening, and rare disease diagnostics. Its microbiome testing services such as SmartGut and GutMap analyse gut bacteria to assess digestive, metabolic, and immune health.

The company’s target segments include individuals seeking preventive health insights, healthcare providers looking to offer personalised medicine, researchers in genomics and microbiome science, and corporates offering employee wellness programmes. Mapmygenome operates a NABL-accredited, CAP-compliant lab and adheres to stringent data privacy standards. It also provides genetic counselling to help users interpret their results.

Edited by Kanishk Singh